Monday, Dec 1
a PSC Research Project [ARCHIVE DISPLAY]
Investigators: Thomas Patrick Shanley, Blake J. Roessler, Brian D. Athey, Marita G. Titler, David Alan Hanauer, Raymond J. Hutchinson, Daniel J. Clauw, Lawrence C. An, Nicholas H. Steneck, Charles Burant, Fernando Jose Martinez, Michael E. Geisser, Alexander Tsodikov, Catherine A. Spino, Claire Z. Kalpakjian, Sarah T. Hawley, Marc A. Zimmerman, Donald Ray Vereen, Susan Lynn Murphy, Dean G. Smith, Robert M. Anderson, David A. Williams, Mark Peter Van Oyen, Marilyn S. Lantz, Nicholas W. Lukacs, Robert A. Bagramian, Barbara L. Brush, Cleopatra Howard Caldwell, Karen Bell Farris, Susan D. Goold, Brooks Andrew Gross, Julie Beth Kaplow, Kelley Kidwell, Michael S. Klinkman, Elizabeth S. Koschmann, Anna L. Kratz, Amy Krentzman, Bethany B. Moore, Christine Anne Rabinak, Donna S. Shewach
The 2007 funding of the Michigan Institute for Clinical and Health Research (MICHR) marked the beginning of a transformation. With growing faculty engagement and federal and institutional support, the University of Michigan has evolved from a predominantly basic science research institution to one with a more comprehensive and synergistic research portfolio. In the past 4 years, extramural funding for clinical and translational research at UM has increased by 27% and since 2008 exceeds basic science funding. In total, 1,280 services have been provided to investigators; 1,950 trainees, staff and faculty have participated in educational venues; 37 trainees have completed certificate and graduate degree programs; fragmented research services have been centralized to create innovative opportunities for users; $10.2M have been distributed for pilot studies; and 52 faculty have participated in the national consortium. In the renewal period, MICHR will further this transformation by pursuing 4 overarching objectives: 1) Create the next generation of clinical and translational researchers and interdisciplinary teams, 2) Develop and enhance capacity-building services that add value, remove barriers, and maximize productivity across the translational research continuum, 3) Create new collaborations and novel approaches to accelerate the pace of driving discoveries to application that impacts health, and 4) Actively lead and contribute to national CTSA consortium activities. By 2017, we will expand education into new areas, strengthen the pipeline of translational researchers, and deploy more flexible and accessible training tools. MICHR will strengthen existing services and launch new ones to impact study start-up times and recruitment. Major informatics investments will fully integrate the needs of clinical and translational researchers into the electronic health record and IT landscape. New practice-based networks will optimize channels for bi-directional translation. Expanded evaluation will more quickly identify and disseminate best practices. We will leverage a significant amount of institutional support to achieve these goals. MICHR will be the engine of continuous improvement and innovation in the conduct of high quality, high impact clinical and translational research to advance the health of Michigan and the nation.
|Funding:||National Center For Research Resources (3UL1RR024986)|
Funding Period: 06/27/2012 to 05/31/2017
This PSC Archive record is displayed for historical reference.